Astellas Pharma
4503.TPharmaceutical
Financials · Standalone
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥888.1bn | ¥789.6bn | ¥688.4bn | ¥613.6bn | ¥542.6bn | ¥545.6bn |
| Operating income | ¥273.4bn | ¥267.3bn | ¥194.0bn | ¥130.6bn | ¥105.9bn | ¥91.9bn |
| Ordinary income | ¥513.1bn | ¥431.1bn | ¥373.3bn | ¥338.2bn | ¥270.5bn | ¥223.4bn |
| Total assets | ¥2.65T | ¥2.56T | ¥2.46T | ¥1.49T | ¥1.39T | ¥1.35T |
| Net assets / equity | ¥1.60T | ¥1.37T | ¥1.18T | ¥1.02T | ¥873.6bn | ¥787.7bn |
| EPS (basic) | ¥205.47 | ¥178.59 | ¥162.92 | ¥172.64 | ¥121.69 | ¥103.95 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 14
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 212 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 80 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 210 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 80 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 210 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 102 figures · EDINET |
| 2022-04-01 → 2023-03-31 | AnnualAmended | 210 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 102 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 80 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 210 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 102 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 102 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 80 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 210 figures · EDINET |
22 more reports are still being processed.